Get the Stockscreener App
783.71
0.19%
-1.46
After Hours:
780.50
-3.21
-0.41%
Regeneron Pharmaceuticals Inc stock is traded at $783.71, with a volume of 267.16K.
It is down -0.19% in the last 24 hours and up +2.92% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$785.17
Open:
$787.99
24h Volume:
267.16K
Relative Volume:
0.25
Market Cap:
$82.37B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
18.76
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+4.52%
1M Performance:
+2.92%
6M Performance:
+50.06%
1Y Performance:
+9.69%
1-Day Range:
$783.61
$792.77
1-Week Range:
$739.23
$792.77
52-Week Range:
$476.49
$792.77
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Brighton Jones LLC Buys 2,335 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Does Regeneron Still Offer Value After Strong Five Year Share Price Gains? - Yahoo Finance
Sanofi Eczema Drug Linked To Lymphoma, Suit Says - Law360
Regeneron Pharmaceuticals's Options Frenzy: What You Need to Know - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year HighHere's What Happened - MarketBeat
Regeneron stock reaches 52-week high at $791.00 - Investing.com
Regeneron Pharmaceuticals Stock (REGN) Opinions on Dupixent Success and Pipeline Developments - Quiver Quantitative
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma - The Manila Times
Regeneron and Sanofi Announce Approval of Dupixent® for Asthma Treatment in Children Aged 6 to 11 in Japan - Quiver Quantitative
Press Release: Sanofi and Regeneron’s Dupixent approved in - GlobeNewswire
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Diabetic Retinopathy Market to See Booming Growth 2025-2032 | - openPR.com
Aug Final Week: Will Regeneron Pharmaceuticals Inc. stock benefit from M&A activityJuly 2025 Snapshot & Safe Swing Trade Setups - moha.gov.vn
Wedge Capital Management L L P NC Buys New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Osaic Holdings Inc. - MarketBeat
Regeneron: The Turnaround Is Gaining Steam - Seeking Alpha
Published on: 2025-12-20 18:02:12 - Улправда
Voya Investment Management LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Corient Private Wealth LLC - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Should Regeneron’s Clarified Eylea Biosimilar Timeline Reshape How REGN Investors View Its Core Franchise? - simplywall.st
Alvotech and Teva Settle With Regeneron on U.S. Launch Timing for Eylea Biosimilar AVT06 - TipRanks
Published on: 2025-12-19 17:35:07 - Улправда
How interest rate cuts could boost Regeneron Pharmaceuticals Inc. stockSwing Trade & Daily Technical Forecast Reports - DonanımHaber
Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $807 From $788, Maintains Buy Rating - marketscreener.com
Texas Permanent School Fund Corp Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. (TEVA:NYSE) - Seeking Alpha
Alvotech and Teva Pharmaceuticals Announce Settlement Agreement with Regeneron for AVT06 Biosimilar Launch in the U.S. - Quiver Quantitative
Eye disease patients may see new Eylea alternative in US from late 2026 - Stock Titan
Regeneron Pharmaceuticals (REGN) Stock Price, Quote, News & History - Benzinga
Will Regeneron Pharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Weekly Recap & Weekly Top Performers Watchlists - Улправда
Clinical momentum lifts biopharma stocks into year-end - BioWorld MedTech
Why (REGN) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Regeneron (REGN) Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration - simplywall.st
Will Regeneron Pharmaceuticals Inc. stock maintain dividend yieldQuarterly Performance Summary & Technical Confirmation Trade Alerts - Улправда
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock split attract more investorsPrice Action & Technical Pattern Recognition Alerts - Bollywood Helpline
Woodstock Corp Acquires 8,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sicart Associates LLC Makes New $3.93 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Leerink Partners raises Regeneron stock price target to $873 on growth outlook - Investing.com UK
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Is Regeneron Still Attractively Priced After Its Recent Share Price Surge? - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple MyelomaSlideshow (NASDAQ:REGN) 2025-12-16 - Seeking Alpha
Westwood Holdings Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Insight Wealth Strategies LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stock Watch: Regeneron Caught Between Success And Expiry - Citeline News & Insights
Praxis Investment Management Inc. Has $762,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Regeneron Pharmaceuticals Inc (REGN)'s Winning Formula: Financia - GuruFocus
Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera - Yahoo Finance
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):